. A: Kaplan Meier curves of PFS in the patients with HR+ BC vs. TNBC regardless of the treatment cohort. B: Kaplan Meier curves of PFS in TNBC patients treated with CV vs. C. C: Kaplan Meier curves of OS in the patients with HR+ BC vs. TNBC regardless of the treatment cohort. D: Kaplan Meier curves of PFS in TNBC patients treated with CV vs. C. The + symbol indicates patients censored at the time of data cut off and analysis. For each comparison, the p value of the Log-rank test is indicated.
Mul variable analysis for OS (including NLR at baseline) C Mul variable analysis for OS (including NLR at baseline)

Months NLR at baseline
Data are presented as n (%) except where otherwise noted. The p value of the  2 test assessing the association between each characteristic and the type of treatment received is indicated in the right column of the table. The p value of the test is indicated in bold numbers when statistically significant. Abbreviations: C: capecitabine; CV: capecitabine and vinorelbine combination; ECOG PS: Eastern Cooperative Oncology Group performance status; HR: hormone receptor; TNBC: triple negative breast cancer; Tx: Treatment.
